Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study

INTERVENTIONS: Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and reimbursed as a third-line therapy for patients with advanced NSCLC by the Taiwan National Health Insurance (NHI) in 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Jason C, Wei, Chen-Fang, Yang, Szu-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429989/
https://www.ncbi.nlm.nih.gov/pubmed/30878976
http://dx.doi.org/10.1136/bmjopen-2018-022293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429989/
https://www.ncbi.nlm.nih.gov/pubmed/30878976
http://dx.doi.org/10.1136/bmjopen-2018-022293

Ejemplares similares